Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

Phase 1 Completed 21 enrolled FORUM Pharmaceuticals Inc

RandomizedParallel-groupTriple-blindTreatment

Summary

This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo when given with the patient's usual antipsychotic medication.

Timeline

Start: 2008-04
Primary completion: 2008-08
Completion: 2008-08

Publications

Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC. Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24. doi: 10.1097/01.pra.0000442935.15833.c5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENCENICLINE	Small molecule	0.3 mg	Oral
Subject	ENCENICLINE	Small molecule	1 mg	Oral
Background	Aripiprazole	Other / unclassified	—	—
Background	Olanzapine	Small molecule	—	—
Background	Paliperidone	Unknown	—	—
Background	Risperidone	Other / unclassified	—	—

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

Summary

Timeline

Publications

Drugs

Indications